Singapore markets closed

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.72+1.26 (+3.46%)
At close: 04:00PM EDT
38.00 +0.28 (+0.74%)
After hours: 05:08PM EDT

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States
203 883 9490

Full-time employees305

Key executives

NameTitlePayExercisedYear born
Mr. Saqib Islam J.D.CEO & Director1.49MN/A1970
Mr. Francis I. Perier Jr., M.B.A.Chief Financial Officer768.24kN/A1960
Dr. Badreddin Edris Ph.D.Chief Operating Officer1.02MN/A1987
Dr. James Cassidy M.D., Ph.D.Chief Medical Officer904.25kN/A1960
Mr. Michael P. NofiChief Accounting OfficerN/AN/A1971
Mr. Tai-An Lin Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Kim DiamondVice President of Communications & Investor RelationsN/AN/AN/A
Mr. Herschel S. Weinstein J.D.General Counsel & Secretary568.64kN/A1957
Mr. Daniel J. PichlChief People Officer428.51kN/A1984
Mr. Bhavesh Ashar M.B.A.Chief Commercial Officer729.62kN/A1966
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Corporate governance

SpringWorks Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2024 is 10. The pillar scores are Audit: 5; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.